Enzolytics Inc (ENZC)

[JL Tan]

Letter from the CEO

On June 19, 2017, the market received a letter from the new Chairman and CEO, Harry Zhabilov. In the letter, market participants could learn about the new market direction of the company after the acquisition of Immunotech. Additionally, it noted the new innovations of the US Patented treatment for HIV/AIDS that Immunotech owns, the quality of life improvement, and the potential demand for this product. If you don’t have time to read the letter, the following were the most significant words:

“- IMMB is the exclusive license holder of an innovative US Patented treatment for HIV/AIDS and Hepatitis C which has successfully completed Phase III clinical testing at one of the leading Hospitals in Europe.
-The treatment “turns on” the immune system to fight Autoimmune diseases which has not been achieved with other therapies. The individuals participating in the clinical trials demonstrated none of the ravaging side effects of many of today’s treatments.
-The Salvage Patients got better and healthier without sacrificing their quality of life.” Source

Additionally, it was noted that the people living with advanced stages of HIV need to pay between $4,000.00 and $25,000.00 per month for the current treatment. IMMB’s 18-week treatment would cost “less than $6,000.00 for the treatment cycle, or $1,500.00 per month“. Hence, the treatment may help most patients in middle and low income countries